Cryoport, Inc.

Cryoport is a global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a strong focus on the cell and gene therapy ("CGT") market. The company's solutions support biopharmaceutical and pharmaceutical companies, animal health markets, reproductive medicine, academic institutions, research, and government agencies. These solutions ensure the safe, compliant storage, handling, and delivery of high-value, temperature-sensitive biological materials, including cell and gene therapies and immunotherapies. Cryoport emphasizes the CGT market, its fastest growing market, by providing specialized, end-to-end supply chain solutions for cell and gene therapy programs from preclinical research, through clinical trials, and to global commercialization. As of December 31, 2025, Cryoport supported 760 clinical trials and 20 commercially approved cell and gene therapies. Its integrated solutions combine advanced logistics, biostorage, kitting and labelling, clinical sample management, collection and cryopreservation services for cell therapies starting materials, cryogenic systems manufacturing, and an informatics platform. These capabilities enable its end-to-end Chain of Compliance®, which includes chain-of-custody, chain-of-condition, and chain-of-identity for complex therapies. The company's solutions maintain the viability, identity, and quality of patient-specific and high-value therapies. Cryoport delivers its services and products through three operating units: Cryoport Systems provides advanced temperature-controlled BioLogistics, BioServices, and cryopreservation solutions; CryoGene delivers long-term temperature-controlled BioStorage and related services; and MVE Biological Solutions (MVE) designs and manufactures cryogenic systems, including freezers, dewars, and transport systems used globally.